Debbie Rigby takes a look at the latest in research news

Vasomotor and physical menopausal symptoms are associated with sleep quality

Sleep disturbance is one of the common complaints in menopause. This observational study of 634 women showed vasomotor and physical menopause symptoms was related to poor sleep quality, specifically sleep latency, habitual sleep efficiency and sleep disturbances. The authors concluded that effective management strategies aimed at reducing menopausal symptoms may improve sleep quality among women around the time of menopause.

PLoS ONE 13(2):e0192934.

 

Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout

In over 6,000 patients with gout and major cardiovascular coexisting conditions, febuxostat was noninferior to allopurinol with respect to rates of adverse cardiovascular events. All-cause mortality and cardiovascular mortality were higher with febuxostat than with allopurinol. This multicentre non-inferiority trial had a median duration of 32 months. Doses of allopurinol were modified according to kidney function and febuxostat doses commenced at 40mg once daily, with an increase to 80mg daily if required to reach target serum uric acid.

New Engl J Med 2018, on-line first March 12

Medscape summary

 

Pain Assessment and Management for Older Patients With Dementia in Hospitals

Pain in older people with dementia is often underestimated and undertreated in acute hospitals. Inadequate pain management attributed to inappropriate pain assessment results in a poor quality of care. This review discusses various pain assessment tools developed to assess pain among older people with dementia.

Pain Manag Nurs. 2018;19(1):54-71. 

 

Comparative cardiovascular safety of nonsteroidal anti‐inflammatory drugs in patients with hypertension

A large cohort study comparing the risk of major cardiovascular events between non-selective NSAIDs and COX-2 inhibitors in patients with hypertension has found no difference in risk between celecoxib, diclofenac, ibuprofen and naproxen. There was a 2-fold increased risk with COX‐2‐selective NSAIDs compared with mefenamic acid.

Br J Clin Pharmacol (2018).